Starling Oncology, Inc. Deferred Tax Assets, Deferred Income
Starling Oncology, Inc. (STLN) had Deferred Tax Assets, Deferred Income of $660.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsDeferredIncome · last filed 2026-03-12
- 2025-12-31: Deferred Tax Assets, Deferred Income $660.00K.
- 2024-12-31: Deferred Tax Assets, Deferred Income $683.00K.
- 2023-12-31: Deferred Tax Assets, Deferred Income $160.00K.
- 2022-12-31: Deferred Tax Assets, Deferred Income $334.00K.
| Period end | Deferred Tax Assets, Deferred Income |
|---|---|
| 2025-12-31 | $660.00K 10-K · filed 2026-03-12 |
| 2024-12-31 | $683.00K 10-K · filed 2026-03-12 |
| 2023-12-31 | $160.00K 10-K · filed 2025-03-26 |
| 2022-12-31 | $334.00K 10-K · filed 2024-03-28 |
| 2021-12-31 | $77.00K 10-K · filed 2023-03-16 |
| 2020-12-31 | $182.00K 10-K · filed 2022-03-11 |